World Library  
Flag as Inappropriate
Email this Article

Cilansetron

Article Id: WHEBN0005753484
Reproduction Date:

Title: Cilansetron  
Author: World Heritage Encyclopedia
Language: English
Subject: Dazopride, Metoclopramide, Azasetron, Batanopride, Ramosetron
Collection: 5-Ht3 Antagonists, Imidazoles, Ketones, Nitrogen Heterocycles
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cilansetron

Cilansetron
Systematic (IUPAC) name
(10R)-10-[(2-methyl-1H-imidazol-1-yl)methyl]-5,6,9,10
-tetrahydro-4H-pyrido(3,2,1-jk)carbazol-11-one
Clinical data
Pregnancy
category
  • C
Legal status
  • Unlicensed
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 87%
Metabolism Hepatic
Biological half-life 1.6 - 1.9 hours
Excretion Renal
Identifiers
CAS Registry Number  Y
ATC code A03
PubChem CID:
IUPHAR/BPS
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL
Chemical data
Formula C20H21N3O
Molecular mass 319.4 g/mol
 Y   

Cilansetron is a drug that is a 5HT-3 antagonist currently under trial phase in the EU and US it is manufactured by Solvay Pharmaceuticals INC.

5HT-3 receptors are responsible for causing many things from nausea to excess bowel movements. It is thought in conditions like irritable bowel syndrome (IBS) the receptors have become faulty or oversensitive. 5HT-3 antagonists work by blocking the nervous and chemical signals from reaching these receptors.

Studies have shown that the drug can greatly improve quality of life in men and women with diahorrea predominant IBS (1) Cilansetron is the first 5HT antagonist specifically designed for IBS that is effective in men as well as women.(1)

Solvay has had considerable difficulty with the medicines regulators in the UK, EU and USA with regards to licensing the drug. This could possibly be due to the problems discovered after licensing with the drug Lotronex. At time of writing; Solvay had recently withdrawn its application to the U.S. Food and Drug Administration (FDA) but was continuing its talks with the MHRA in the UK and EU regulators. (2)

It is not currently known what sort of timeframe the public are looking at to be able to obtain the drug. This matter is not helped by the lack of information about cilansetron and its trials in the public domain. The regulators have also stated this in their responses.

There is no information about future trials currently available.

Some people have tried the Anti-emetic ondansetron HCl (Zofran) as a substitute for the time being, results are mixed but noted effect has been shown in some males and females (3) However; due to its license in the UK it is usually only prescribable at consultant level. Since the licensing of a generic version it is more likely an NHS prescription will be accepted as the branded version is very expensive (Official NHS pricing.) In the USA and Canada: availability often depends on insurance and the doctors personal opinion on off-label prescribing.

References

  1. http://www.drugdevelopment-technology.com/projects/cilanserton (General info on Cilansetron.)
  2. http://www.solvaypress.com/pressreleases/0,,36423-2-0,00.htm#contact (Sovay press relaase 19 November 2005.)
  3. http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2036.1996.30172000.x (Clinical trial for 5-HT3 antagonists use in Diarrhoea-predominant IBS)
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.